Skip to main
  1. Stocks
  2. Tiziana Life Sciences Ltd
  3. Forecast
TLSA

TLSA Stock Forecast & Price Target

TLSA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tiziana Life Sciences is supported by a compelling, mechanism-driven thesis centered on intranasal foralumab, which has repeatedly shown TSPO-PET reductions, Treg stimulation, and lower CNS inflammation across SPMS, MSA, and AD. The near-term catalyst is the 48-patient INFORM-MS Phase 2a readout expected in October 2026, with the last patient completing the last visit on 9/21/26, and a meaningful signal could de-risk the broader pipeline, especially given reported stability or improvement in all 14 Expanded Access Program patients within 6 months. Its attractiveness is further reinforced by no serious adverse events across 37 patient years of exposure, orphan-like unmet need in SPMS and MSA, and a broad patent estate that extends core foralumab protection to 2037 with additional families potentially lasting into 2042 to 2046.

Bears say

Tiziana Life Sciences is viewed negatively because its clinical-stage pipeline faces unusually high scientific and regulatory risk: neuroscience is complex, drug discovery is inherently risky, and the FDA may demand larger, well-controlled datasets and possibly two trials for full approval in SPMS, MSA, and AD. As a small biopharmaceutical company with no approved products and a limited operating history, it has incurred significant operating losses since inception and will likely need substantial additional capital, with financing constraints risking delays or scaled-back development. Foralumab also faces mechanistic uncertainty, potential weaker efficacy in later-stage patients, intensifying competition in neuroinflammation, and third-party dependency risk because patent prosecution for licensed technology is controlled by NovImmune and Brigham and Women’s Hospital.

TLSA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tiziana Life Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

TLSA Analyst Forecast & Price Prediction

Get the latest TLSA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tiziana Life Sciences Ltd (TLSA) Forecast

Analysts have given TLSA a Strong Buy based on their latest research and market trends.

According to 1 analysts, TLSA has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tiziana Life Sciences Ltd (TLSA)


TLSA Analyst Forecast & Price Prediction

Get the latest TLSA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TLSA stock data and trends